Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623129 | 1.00 | ACP1 (0.39) | ACP1P2RX3MAT2AHTR7 | |
| SCHEMBL24089897 | 0.90 | ACP1 (0.40) | ACP1MAT2A | |
| SCHEMBL29623150 | 0.90 | ACP1 (0.40) | ACP1MAT2A | |
| SCHEMBL23064459 | 0.88 | LMNA (0.39) | ACP1 | |
| SCHEMBL23065257 | 0.86 | DRD2 (0.39) | — | |
| SCHEMBL29623121 | 0.86 | DRD2 (0.39) | — | |
| SCHEMBL23065073 | 0.85 | ACP1 (0.48) | ACP1 | |
| SCHEMBL29623137 | 0.84 | ACP1 (0.40) | ACP1P2RX3HTR7 | |
| SCHEMBL23045336 | 0.84 | ACP1 (0.40) | ACP1P2RX3HTR7 | |
| SCHEMBL23065072 | 0.84 | ACP1 (0.52) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| WO-2021039968-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | ACP1 3959/4885P2RX3 336/4885MAT2A 4390/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | ACP1 4435/4885P2RX3 370/4885MAT2A 4098/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | ACP1 4435/4885P2RX3 370/4885MAT2A 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.